We anticipate that we will make determinations as to which programs to pursue and how much funding to direct to each program on an ongoing basis. We are currently focusing our resources on advancing the development of our non-partnered programs: celgosivir and MX-2401.
General and Corporate Expenses
General and corporate expenses in Q3/08 were $0.9 million (Q3/07: $0.9 million) and were $2.7 million for YTD Fiscal 2008 (YTD Fiscal 2007: $2.7 million). Personnel costs were $0.5 million in Q3/08 (Q3/07: $0.7 million) and were $1.5 million for YTD Fiscal 2008 (YTD Fiscal 2007: $1.8 million).
Amortization expense for property and equipment was $0.2 million in YTD Fiscal 2008 (YTD Fiscal 2007: $0.2 million).
Amortization expense for intangible assets was $0.2 million in YTD Fiscal 2008 (YTD Fiscal 2007: $0.5 million).
Write-down of Intangible Assets
Pursuant to the quarterly review of intangible assets for Q3/08 the Company determined that a $0.5 million write-down was appropriate in respect of a technology acquired as part of our August 2004 merger with MitoKor. The write-down of intangible assets in Q3/08 and YTD Fiscal 2008 was $0.5 million. The $3.3 million write-down in Q3/07 and YTD Fiscal 2007 related to the Company's MX-4509 program.
Other Income and Expenses
Interest income was $0.4 million for YTD Fiscal 2008 (YTD Fiscal 2007: $0.4 million).
Accretion expense related to the convertible royalty participation
units for Q3/08 was $0.5 million (Q3/07: $0.4 million) and is $1.3 million
for YTD Fiscal 2008 (YTD Fiscal 2007: $1.1 million). This accretion expense
is a non-cash expense resulting from (i) accreting the liability component
|SOURCE MIGENIX Inc.|
Copyright©2008 PR Newswire.
All rights reserved